Boston Scientific to acquire the rest of Veniti for $108mm plus earn-outs
Executive Summary
Boston Scientific Corp. agreed to paid $108mm in cash up front to acquire the remaining 75% of cardiovascular stent developer Veniti Inc. that it does not already own. The deal also includes up to $52mm in in earn-outs tied to FDA approval of Veniti’s flagship product.
Deal Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Final
Deal Type
-
Acquisition
- Includes Earnout
- Partial Acquisition
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice